Eptinezumab

Eptinezumab May Provide Fast, Effective Reduction of Monthly Migraine Days

Eptinezumab May Provide Fast, Effective Reduction of Monthly Migraine Days

By

Eptinezumab has shown 100% bioavailability when administered intravenously.

Intravenous Eptinezumab Effectively Reduces Monthly Migraine Days

Intravenous Eptinezumab Effectively Reduces Monthly Migraine Days

By

More patients in the 100 mg and 300 mg eptinezumab groups achieved a 100% reduction in monthly migraine days over the 112 weeks compared with placebo.

Eptinezumab for Frequent Episodic Migraine: Results of Phase 3 PROMISE-1 Study

Eptinezumab for Frequent Episodic Migraine: Results of Phase 3 PROMISE-1 Study

By

Eptinezumab, a humanized monoclonal antibody specific to calcitonin gene-related peptide, may be an effective prophylactic for individuals with frequent episodic migraines.

Sign Up for Free e-Newsletters